X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
PCN-101 (R-ketamine), a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-suicidal effects.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant activity and anti-suicidal effects. Pharmacologically, PCN-101 is a non-competitive NMDA receptor antagonist.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
PCN-101 (R-ketamine), demonstrated an encouraging safety profile and signals of efficacy across all timepoints despite not achieving statistical significance on the primary endpoint.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
PCN-101 (R-ketamine) is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant (RAAD) activity and anti-suicidal effects.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators with the potential for rapid-acting antidepressant (RAAD) activity and anti-suicidal effects. Pharmacologically, PCN-101 is a non-competitive NMDA receptor antagonist.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
In the aggregate, these renewed lock-up agreements represent over 30% of atai’s outstanding common shares and illustrate the confidence of atai’s key shareholders in atai’s platform and its potential to address the growing mental health crisis including its lead asset PCN-101.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apeiron Investment Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 15, 2021
Details:
Company initiate, Phase 2a clinical study to evaluate the safety and efficacy of PCN-101 (R-ketamine), a stereoisomer of ketamine being developed for therapeutic treatment of psychiatric disorders such as TRD.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2021
Details:
Integration of Introspect’s digital therapeutic with R-ketamine therapy for patients with treatment resistant depression.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 09, 2021
Details:
Under the terms of the license, Otsuka will have exclusive rights to develop and commercialize products containing PCN-101 in Japan. Otsuka will undertake development, regulatory, and commercialization activities in Japan, with input and guidance from both companies.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $20.0 million
Deal Type: Collaboration March 16, 2021
Details:
PCN-101 was safe and well-tolerated at all doses up to 150 mg, the highest dose tested. There were no serious adverse events reported. The pharmacokinetics of PCN-101 in plasma were approximately dose-proportional.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2021
Details:
Proceeds from the financing will be used primarily to fund pre-clinical and clinical development of ATAI's existing mental health programs, to expand its drug candidate pipeline and further advance ATAI's platform technologies.
Lead Product(s): R-Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apeiron Investment Group
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
